Promising Advances in Cholesterol-Lowering Medications

Recent clinical trials have unveiled two promising oral medications aimed at significantly reducing cholesterol levels, potentially transforming the landscape of cardiovascular disease prevention. The first, TLC-2716, demonstrated a remarkable ability to lower remnant cholesterol by over 60% and triglycerides by nearly 40% in a phase 1 trial involving 100 healthy adults. This compound targets the Liver X Receptor ? (LXR?), a metabolic switch that regulates fat metabolism in the liver and gut. The trial, which lasted 14 days and was partly funded by OrsoBio, showed that TLC-2716 effectively reduced fat synthesis and absorption without adversely affecting LXR? activity in other body areas.

ScienceAlertExperimental pill dramatically reduces ‘bad’ cholesterol

The second medication, enlicitide, has shown similar efficacy in a phase 3 trial, reducing low-density lipoprotein (LDL) cholesterol levels by approximately 60% among 2,909 participants with established atherosclerosis or at high risk. This drug operates by binding to the PCSK9 protein, which plays a critical role in cholesterol metabolism. The trial results indicate that enlicitide could provide a significant oral alternative to existing therapies, particularly for patients who struggle to meet cholesterol goals despite statin use.

Experimental pill dramatically reduces ‘bad’ cholesterol

Both drugs represent advancements in lipid management strategies. TLC-2716 works by selectively inhibiting fat production and enhancing fat clearance, while enlicitide mimics the action of monoclonal antibodies that inhibit PCSK9. The implications of these findings are substantial, as they offer new avenues for treating hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease (MASLD), conditions that contribute to cardiovascular risks.

ScienceAlert

The researchers behind TLC-2716, led by Johan Auwerx from the Swiss Federal Institute of Technology in Lausanne, emphasize the importance of developing compounds that target specific metabolic pathways without disrupting beneficial cholesterol functions elsewhere in the body. Similarly, Ann Marie Navar, M.D., from UT Southwestern Medical Center, highlighted that enlicitide's oral administration could enhance patient compliance and accessibility.

Experimental pill dramatically reduces ‘bad’ cholesterol

The study on TLC-2716, published in *Nature Medicine*, notes that "all doses of TLC-2716 were safe and well tolerated," indicating a favorable safety profile. Researchers expressed optimism about the drug's potential benefits for individuals with higher lipid levels, although they cautioned that results must be interpreted cautiously. Meanwhile, the enlicitide trial results, published in *The New England Journal of Medicine*, suggest that "these reductions in LDL cholesterol are the most we have ever achieved with an oral drug by far since the development of statins," underscoring the drug's potential impact on cardiovascular disease prevention.

ScienceAlert

Despite the promising results, some experts remain cautious. Concerns about long-term efficacy and safety, particularly regarding the metabolic effects of these new compounds, have been raised. Additionally, the high costs associated with new lipid-lowering therapies may limit their accessibility for many patients, a challenge that has historically hindered the widespread adoption of effective cholesterol management strategies.

ScienceAlert

Both TLC-2716 and enlicitide are poised for further clinical testing. The next steps include longer trials focusing on overweight and obese individuals with poor lipid profiles, as researchers aim to confirm the drugs' effectiveness in broader populations. As these studies progress, the potential for these medications to reshape cardiovascular disease prevention strategies remains a significant area of interest in the medical community.

ScienceAlert